Document Detail

Tolerability of aminosalicylates in inflammatory bowel disease.
MedLine Citation:
PMID:  11437696     Owner:  NLM     Status:  MEDLINE    
Since its synthesis in the 1930s and subsequent introduction, sulfasalazine has been an effective treatment for inflammatory bowel disease. However, up to one-third of patients are unable to take the drug because of severe intolerance. The finding in 1977 that the anticolitic effect of sulfasalazine lay in its 5-aminosalicylic [(5-ASA); mesalazine] moiety led to the development of new generations of 5-ASA agents. These new agents include a slow continuous release formulation, pH-dependent release formulations, formulations using alternative carrier molecules and rectally administered formulations. Newer 5-ASA formulations are more effective than placebo in maintaining remission of ulcerative colitis. They have also been used for the treatment of active Crohn's disease as well as maintenance treatment of ileocolonic Crohn's disease, although their role in isolated small bowel disease is controversial. In general terms, all of the newer 5-ASA preparations are much better tolerated than sulfasalazine. The use of standard dosages of mesalazine in pregnancy appears to be tolerated; however, continuing surveillance of pregnancy outcome is recommended. While there is evidence that mesalazine can cause nephrotoxic reactions, these reactions can occur with all 5-ASA-containing preparations, particularly in individuals with existing renal disease. Blood dyscrasias can also occur with all aminosalicylates.
S Ishaq; J R Green
Related Documents :
12235076 - Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of s...
11418406 - Hydrocolonic sonography for evaluating inflammatory bowel disease.
18366306 - Classification of genetic profiles of crohn's disease: a focus on the atg16l1 gene.
8543366 - Pharmacological activity of the second generation leukotriene b4 receptor antagonist, s...
11478196 - Impairment rating of the cardiovascular system: idiopathic cardiomyopathy.
24720646 - Treat to target in spondyloarthritis: the time has come.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy     Volume:  15     ISSN:  1173-8804     ISO Abbreviation:  BioDrugs     Publication Date:  2001  
Date Detail:
Created Date:  2001-07-04     Completed Date:  2001-08-16     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9705305     Medline TA:  BioDrugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  339-49     Citation Subset:  IM    
Queen Elizabeth Hospital, Birmingham, England.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aminosalicylic Acids / adverse effects*,  therapeutic use
Inflammatory Bowel Diseases / drug therapy*
Reg. No./Substance:
0/Aminosalicylic Acids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Immunological aspects of alzheimer's disease: therapeutic implications.
Next Document:  Serum leptin levels in pregnant women with type 1 diabetes mellitus.